Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company focused on vaccines, using a platform that combines protein-based nanoparticles with its proprietary Matrix-M® adjuvant. News about Novavax often centers on its COVID-19 vaccine Nuvaxovid™/Nuvaxovid®, its broader infectious disease pipeline, and the progress of key partnerships and collaborations.
Recent announcements highlight Novavax’s collaboration and license agreement with Sanofi, under which Sanofi has taken on lead commercial and regulatory responsibilities for Nuvaxovid in selected markets. News items cover marketing authorization transfers in the European Union and United States, milestone payments to Novavax, and Sanofi’s clinical data on combination vaccine candidates that incorporate Nuvaxovid and Matrix-M. Updates also describe regulatory approvals in markets such as Japan through partner Takeda, triggering additional milestone payments and royalty opportunities.
Investors following NVAX news will see regular coverage of quarterly financial results, revenue composition from product sales, supply sales and licensing and royalty streams, as well as information on Novavax’s site consolidation and cost footprint in Maryland. The company’s communications also describe early-stage research on vaccine candidates for shingles, Clostridioides difficile colitis and respiratory syncytial virus combinations, and the use of Matrix-M in the R21/Matrix-M malaria vaccine developed with Serum Institute of India and Oxford University.
This page aggregates press releases, conference participation announcements, regulatory updates and other material events related to Novavax. Readers can use it to monitor developments in the company’s vaccine programs, partnership milestones, capital structure transactions and strategic transformation as disclosed in public statements.
Novavax and SK bioscience have submitted a Biologics License Application (BLA) for NVX-CoV2373, the first protein-based COVID-19 vaccine candidate for BLA in South Korea. This submission signifies the first full approval request for the vaccine globally. Novavax aims to provide broad access to the vaccine, with a deal to supply 40 million doses to the South Korean government. The vaccine shows high efficacy in various trials, promising a vital tool in combating COVID-19.
Novavax, Inc. (NASDAQ: NVAX) reported its third-quarter 2021 results with a revenue of $178.8 million, up from $157.0 million year-on-year. The company faced a net loss of $322.4 million or $4.31 per share, compared to a loss of $197.3 million or $3.21 per share last year. Highlights included emergency use authorization for its COVID-19 vaccine in Indonesia and advanced purchase agreements for 20 million doses with the European Commission. Cash reserves as of September 30, 2021, reached $1.9 billion, primarily from advance purchase payments.
On November 4, 2021, Novavax (Nasdaq: NVAX) announced the completion of its rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its COVID-19 vaccine candidate, NVX-CoV2373. This submission includes clinical data from pivotal Phase 3 trials showing 90.4% overall efficacy. The vaccine demonstrated 100% protection against severe disease and has received authorization in Indonesia. Novavax also plans to submit a complete package to the U.S. FDA by year-end to broaden global access through the COVAX Facility.
Novavax has submitted its protein-based COVID-19 vaccine, NVX-CoV2373, for provisional approval to New Zealand's Medsafe, marking a significant step in global vaccine distribution. The submission includes all necessary modules, such as Chemistry, Manufacturing, and Controls (CMC), backed by phase 3 trial data showing 100% protection against moderate and severe disease and 90.4% overall efficacy. With additional regulatory filings in the UK, Australia, and Canada, Novavax is focused on optimizing its global vaccine strategy while thanking the New Zealand government for its partnership.
Novavax, Inc. (Nasdaq: NVAX) and Serum Institute of India have received Emergency Use Authorization (EUA) from Indonesia's National Agency of Drug and Food Control for COVOVAX™, a protein-based COVID-19 vaccine. This marks a significant milestone as it is the first regulatory approval globally for a protein-based COVID-19 vaccine based on Phase 3 clinical data. Novavax expects additional authorizations soon in various countries, including India and the Philippines. The vaccine's stable storage conditions will enhance distribution accessibility in Indonesia.
Novavax, Inc. (Nasdaq: NVAX) has completed its rolling submission to Health Canada for its COVID-19 vaccine candidate, marking the first protein-based vaccine submitted for regulatory review in Canada. Additionally, all required data modules for the European Medicines Agency (EMA) have been submitted. The vaccine, NVX-CoV2373, showed 100% protection against moderate and severe disease and 90.4% efficacy overall in a Phase 3 trial with 30,000 participants. The company aims to file for Conditional Marketing Authorization in the EU and anticipates submitting a complete package to the U.S. FDA by year-end.
Novavax, Inc. (Nasdaq: NVAX) has completed its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its protein-based COVID-19 vaccine candidate, NVX-CoV2373, in Australia. This marks the first complete application for a protein-based COVID-19 vaccine in the country. The TGA submission includes data from pivotal Phase 3 trials, demonstrating efficacy rates of 96.4% against the original virus strain and 90.4% overall. Novavax plans further submissions in key markets, including the U.S., U.K., and Europe, with a goal to enhance global access to its vaccine.
Novavax, Inc. has completed its regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its protein-based COVID-19 vaccine, NVX-CoV2373. This marks the first authorization submission for a protein-based COVID-19 vaccine in the U.K. The vaccine demonstrated high efficacy rates of 96.4% against the original virus and 89.7% overall in trials involving ~45,000 participants. Novavax plans to submit to additional global authorities, including the EU, Canada, and Australia, soon, with FDA submission expected by the end of 2021.
Novavax, Inc. (Nasdaq: NVAX) announces it will report its third quarter 2021 financial results on November 4, 2021, post-market close. The company will host a conference call at 4:30 p.m. EDT to discuss its operational highlights. Participants are encouraged to join early for a timely connection. A replay will be available from 7:30 p.m. EDT on the same day until November 11, 2021. Novavax focuses on developing innovative vaccines to combat serious infectious diseases, including COVID-19 and influenza.
Novavax, Inc. (Nasdaq: NVAX) announced that Dr. Vivek Shinde will present at the World Vaccine Congress Europe 2021 on October 20, 2021. The focus will be on the COVID-NanoFlu™ Combination Vaccine, a novel formulation that integrates the company's COVID-19 and NanoFlu™ vaccine candidates using the Matrix-M™ adjuvant.
The session is scheduled from 11:30 a.m. to 12:00 p.m. CET (5:30 a.m. to 6:00 a.m. EDT). For details, visit the Congress website.